Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24698219 | 0.93 | HRH3 (0.52) | HRH3CYP2D6FAAHMBTD1L3MBTL3 | |
| SCHEMBL1788210 | 0.93 | HRH3 (0.56) | HRH3CYP2D6 | |
| SCHEMBL4573212 | 0.89 | CARM1 (0.42) | HRH3FAAHPNMT | |
| SCHEMBL24698220 | 0.86 | L3MBTL3 (0.48) | HRH3FAAHMBTD1L3MBTL3 | |
| SCHEMBL24698754 | 0.86 | L3MBTL3 (0.48) | HRH3FAAHMBTD1L3MBTL3 | |
| SCHEMBL28587390 | 0.80 | CARM1 (0.41) | HRH3FAAHASIC3MBTD1L3MBTL3 | |
| SCHEMBL27228180 | 0.80 | L3MBTL3 (0.59) | HRH3CYP2D6FAAHKCNH2MBTD1 | |
| SCHEMBL29041981 | 0.79 | PRMT5 (0.39) | HRH3FAAHASIC3 | |
| SCHEMBL30508272 | 0.79 | PRMT5 (0.39) | HRH3PNMT | |
| SCHEMBL26963045 | 0.79 | HRH3 (0.47) | HRH3CYP2D6FAAHPNMTASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2022246179-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | AXL, BTK, MERTK | HRH3 2491/4885CYP2D6 4251/4885FAAH 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.